Ex Vivo Study of Immune-Reconstitution Kinetics in HIV-infected ARV-naive Subjects, With Advanced Disease, Starting a Darunavir/Ritonavir or Efavirenz Based HAART (IMMUNO Study)
Phase of Trial: Phase IV
Latest Information Update: 25 Nov 2013
At a glance
- Drugs Darunavir/ritonavir (Primary) ; Efavirenz (Primary) ; Emtricitabine/tenofovir disoproxil fumarate
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms IMMUNO
- Sponsors Janssen-Cilag
- 07 Jun 2017 Biomarkers information updated
- 05 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Mar 2013 Planned end date changed from 1 Dec 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.